OrthoPediatrics (NASDAQ:KIDS) Sees Strong Trading Volume - What's Next?

Key Points

• OrthoPediatrics shares saw an 80% surge in trading volume, with about 309,963 shares changing hands, while the stock edged up to $22.001.
• Analyst sentiment remains favorable: nine analysts rate the stock a Buy, with an overall “Moderate Buy” consensus and an average price target of $26.44.
• The company exceeded quarterly expectations, reporting a $0.26 per-share loss versus the anticipated $0.30 loss and revenue of $70.51 million; however, insiders have sold roughly 1.19 million shares worth $27.7 million over the past 90 days.

Shares of OrthoPediatrics Corp. (NASDAQ:KIDS - Get Free Report) saw unusually-high trading volume on Thursday . Approximately 309,963 shares traded hands during trading, an increase of 80% from the previous session's volume of 171,784 shares.The stock last traded at $22.0010 and had previously closed at $21.68.

Wall Street Analyst Weigh In

Several research firms have issued reports on KIDS. Weiss Ratings upgraded shares of OrthoPediatrics from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Wednesday, August 5th. BTIG Research increased their price objective on OrthoPediatrics from $24.00 to $29.00 and gave the stock a "buy" rating in a research report on Thursday, August 20th. Piper Sandler restated an "overweight" rating and set a $25.00 target price (up from $22.00) on shares of OrthoPediatrics in a research report on Wednesday, August 5th. TD Cowen reaffirmed a "buy" rating on shares of OrthoPediatrics in a report on Monday, June 15th. Finally, Truist Financial set a $22.00 price objective on OrthoPediatrics in a report on Wednesday, August 5th. Nine analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, OrthoPediatrics currently has an average rating of "Moderate Buy" and an average price target of $26.44.

OrthoPediatrics Stock Down 0.7%

The company has a market cap of $562.25 million, a PE ratio of -12.82 and a beta of 0.99. The stock's 50 day moving average price is $21.94 and its 200-day moving average price is $18.99. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.17 and a current ratio of 4.78.

OrthoPediatrics (NASDAQ:KIDS - Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.04. The business had revenue of $70.51 million during the quarter, compared to the consensus estimate of $68.21 million. OrthoPediatrics had a negative net margin of 15.72% and a negative return on equity of 8.10%. On average, analysts predict that OrthoPediatrics Corp. will post -1.14 earnings per share for the current year.

Insider Activity at OrthoPediatrics

In other OrthoPediatrics news, major shareholder Jennifer Pritzker sold 326,700 shares of the company's stock in a transaction that occurred on Friday, August 28th. The stock was sold at an average price of $23.04, for a total transaction of $7,527,168.00. Following the completion of the transaction, the insider owned 6,536,764 shares of the company's stock, valued at $150,607,042.56. This represents a 4.76% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director David Pelizzon sold 326,700 shares of the business's stock in a transaction that occurred on Friday, August 28th. The shares were sold at an average price of $23.04, for a total value of $7,527,168.00. Following the transaction, the director directly owned 6,536,764 shares in the company, valued at $150,607,042.56. This trade represents a 4.76% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 1,192,893 shares of company stock worth $27,689,613 in the last 90 days. Company insiders own 32.50% of the company's stock.

Institutional Investors Weigh In On OrthoPediatrics

A number of large investors have recently modified their holdings of KIDS. Squarepoint Ops LLC raised its stake in OrthoPediatrics by 95.0% in the second quarter. Squarepoint Ops LLC now owns 195,468 shares of the company's stock worth $3,739,000 after buying an additional 95,230 shares in the last quarter. Waverly Advisors LLC raised its position in shares of OrthoPediatrics by 6.7% in the 2nd quarter. Waverly Advisors LLC now owns 12,366 shares of the company's stock worth $237,000 after acquiring an additional 775 shares in the last quarter. California State Teachers Retirement System lifted its stake in shares of OrthoPediatrics by 397.1% in the 2nd quarter. California State Teachers Retirement System now owns 4,553 shares of the company's stock valued at $87,000 after purchasing an additional 3,637 shares during the period. Nantahala Capital Management LLC purchased a new stake in OrthoPediatrics in the second quarter worth $4,636,002. Finally, Grandeur Peak Global Advisors LLC bought a new position in OrthoPediatrics in the second quarter worth $954,000. Institutional investors own 69.05% of the company's stock.

About OrthoPediatrics

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company's product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.